Is Alto Neuroscience Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Alto Neuroscience Inc (ANRO) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Alto Neuroscience Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Alto Neuroscience Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Alto Neuroscience Inc?

Muslim investors may consider investing in Alto Neuroscience Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Alto Neuroscience Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Alto Neuroscience Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Alto Neuroscience Inc updated?

The Shariah compliance status of Alto Neuroscience Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Alto Neuroscience Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Alto Neuroscience Inc?

You can check the latest Shariah compliance status of Alto Neuroscience Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ANRO Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 17, 2026

Report Source: 2025 Annual Report

Alto Neuroscience Inc. Stock Analysis ANRO

United States Health Care Small Cap Report: 2025 Annual

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 68 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.

Key Statistics of Alto Neuroscience Inc (ANRO)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$22.41$23.50

Today's Open

$23.04

Volume

376.33K

P/E Ratio (TTM)

52 Week Range

$2.15$28.44

Market Cap

813.01M

Avg. Volume

304.32K

Dividend Yield

Financial Metrics & Statements of Alto Neuroscience Inc (ANRO)

FAQ's for Alto Neuroscience Inc (ANRO)

According to Musaffa’s Shariah screening methodology, Alto Neuroscience Inc (ANRO) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.